Prevention of hyperoxia-induced bronchial hyperreactivity by sildenafil and vasoactive intestinal peptide: impact of preserved lung function and structure

Abstract

Objective Hyperoxia exposure leads to the development of lung injury and bronchial hyperreactivity (BHR) via involvement of nitric oxide (NO) pathway. We aimed at characterizing whether the stimulation of the NO pathway by sildenafil or vasoactive intestinal peptide (VIP) is able to prevent the hyperoxia-induced development of BHR. The respective roles of the preserved lung volume and alveolar architecture, the anti-inflammatory and anti-apoptotic potentials of these treatments in the diminished lung responsiveness were also characterized. Materials and methods Immature (28-day-old) rats were exposed for 72 hours to room air (Group C), hyperoxia (>95%, Group HC), or hyperoxia with the concomitant administration of vasoactive intestinal peptide (VIP, Group HV) or sildenafil (Group HS). Following exposure, the end-expiratory lung volume (EELV) was assessed plethysmographically. Airway and respiratory tissue mechanics were measured under baseline conditions and following incremental doses of methacholine to assess BHR. Inflammation was assessed by analyzing the bronchoalveolar lavage fluid (BALF), while biochemical and histological analyses were used to characterize the apoptotic and structural changes in the lungs. Results The BHR, the increased EELV, the aberrant alveolarization, and the infiltration of inflammatory cells into the BALF that developed in Group HC were all suppressed significantly by VIP or sildenafil treatment. The number of apoptotic cells increased significantly in Group HC, with no evidence of statistically significant effects on this adverse change in Groups HS and HV. Conclusions These findings suggest that stimulating the NO pathway by sildenafil and VIP exert their beneficial effect against hyperoxia-induced BHR via preserving normal EELV, inhibiting airway inflammation and preserving the physiological lung structure, whereas the antiapoptotic potential of these treatments were not apparent in this process.

Continuous intravenous sildenafil as an early treatment in neonates with congenital diaphragmatic hernia

“…Inhibition of PDE5 increases intracellular cGMP levels leading to vasodilation. Several animal studies demonstrated an improvement in angiogenesis, alveolarization, and hyperoxia‐induced changes in the NO‐sGC‐cGMP pathway associated with the use of sildenafil . Furthermore, PDE5 inhibition is associated with antiproliferative effects on pulmonary artery cells …”

Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?

“…In addition, Watanabe et al 50 pointed out that sildenafil use decreases pulmonary vascular resistance and improves dyspnea in patients with interstitial pneumonia. In their work, Gammella et al 51 revealed that sildenafil and erythropoietin treatments protect endothelial cells in hypoxic states, whereas Czövek et al 52 reported that sildenafil use prevents the hyperoxia-induced development of bronchial hyperreactivity by preserving the normal end-expiratory lung volume and inhibiting airway inflammation. Although hydrogen sulfide (H 2 S) was reported as an endogenous inhibitor of PDE activity, 53 sildenafil use has been demonstrated to promote remarkably intracellular H 2 S production that controls proliferation in the pulmonary arterial smooth muscle cells by inducing vasodilation and reducing oxidative stress and inflammation.…”

Blockade of the cholinergic system during sensitization enhances lung responsiveness to allergen in rats

“…The BALF was centrifuged in a 2 mL Eppendorf tube (750 rpm for 7 minutes). The supernatant was removed, and the pellet was re‐suspended in an adequate quantity of PBS to obtain a concentration of 10 4 cells/100 μL. For cytological evaluation, a cytospin was performed with 100 μL of the suspended cells.…”